**MEMORANDUM**

**TO:** NovaCrest Research Executive Team & Site Investigators
**FROM:** Outside Counsel
**DATE:** Wednesday, 10:30 a.m. (Day of Discovery)
**SUBJECT:** IMMEDIATE ACTION REQUIRED: Material Consent Omission (Version 4.2 Error)

Based on the Governing Law applicable to this study and the facts provided, we must immediately mitigate regulatory risk and protect subject rights. The following plan directs specific actions regarding enrollment holds, reporting, re-consent, data integrity, and the timeline for correction.

### 1. Immediate Enrollment and Intervention Holds
**Directive:** Immediately suspend all new enrollment across all five sites. Simultaneously, halt all nonurgent research interventions (including scheduled implants) for any subject enrolled under version 4.2 or where the consent version is unknown.
**Rationale:** Rule 2 mandates stopping nonurgent research under defective forms until an Ethics Board (EB) approves corrected materials. Rule 1 requires valid informed consent *before* any intervention; the proposed "email after implantation" plan by site investigators is a direct violation of Rule 1 and Rule 5.

### 2. Care and Safety Follow-up Continuity
**Directive:** Routine medically necessary safety visits (including the six scheduled this week) **must continue**. However, no research-specific procedures (e.g., device interrogation for study data) may occur during these visits until re-consent is obtained.
**Rationale:** Rule 3 prohibits abandoning subjects or withholding care to preserve a study pause. The sites must clarify to subjects that medical safety monitoring continues uninterrupted, even if research data collection pauses.

### 3. Ethics-Board and Regulator Reporting Clocks
**Directive:** Initiate reporting immediately upon discovery (Wednesday).
*   **Central Ethics Board:** Formal notification of the consent noncompliance must be submitted no later than **Tuesday end-of-day** (5 business days: Wed, Thu, Fri, Mon, Tue). Utilize the emergency review scheduled for Thursday to submit a preliminary report and expedite the corrected material approval.
*   **Device Regulator:** Report must be filed within **7 calendar days** (Next Wednesday by 10:00 a.m.).
*   **Site Reporting:** Verify if any site local protocol requires reporting faster than 5 business days; if so, comply immediately per Rule 4.

### 4. Emergency Approval of Corrected Materials
**Directive:** Convene the Central Ethics Board emergency review **tomorrow (Thursday)**. Submit a corrected consent form incorporating the nerve-weakness paragraph explicitly, along with a draft communication plan for subjects regarding the error.
**Rationale:** Per Rule 2, interventions cannot resume without EB approval of corrected materials. The emergency review is necessary to minimize disruption to the 12 subjects scheduled for implantation in the next 72 hours.

### 5. Re-consent of Subjects Awaiting Intervention
**Directive:** For the 12 subjects scheduled for implantation (4 known v4.2, 8 unknown version):
1.  **Hold:** All procedures are cancelled until EB approval is received Thursday.
2.  **Verify:** Confirm consent version for the 8 "unknown" subjects immediately via site logs and PDF retrieval (Rule 9).
3.  **Re-consent:** Once the corrected form is EB-approved, all 12 subjects must sign the new approved form before their implantation can proceed.
**Rationale:** Rule 5 requires re-consent on an approved corrected form before the next nonurgent intervention. You cannot proceed on v4.1 or v4.3 assumptions for the "unknown" group; verification is mandatory.

### 6. Notice and Consent Choices for Subjects Who Completed Intervention
**Directive:** Develop a disclosure script for the 38 subjects confirmed on v4.2 who already received implants, as well as any other subjects in the 62-unknown pool who have completed interventions.
1.  Notify them of the omission error.
2.  Disclose the specific material risk (temporary nerve weakness) they were not previously told.
3.  Inquire if they wish to continue safety follow-up or data use now that the full risk is known.
**Rationale:** Rule 6 requires providing new risk information when it affects safety follow-up or willingness to permit data use. Consent cannot be backdated; this must be recorded as a new disclosure event.

### 7. Treatment of Previously Collected Data
**Directive:** Suspend any internal decision to discard or purge data from v4.2 subjects. Preserve all data sets currently.
**Rationale:** Per Rule 7, data is not automatically discarded. The Central Ethics Board will determine the permissibility of continued data use after reviewing the noncompliance nature and subject wishes.

### 8. Specific Records Needed to Determine Affected Population
**Directive:** Execute a version audit for all 120 subjects immediately. Do not rely on the central database enrollment dates alone.
*   **Required Records:** Version-controlled document logs, original signed PDFs (with metadata), site consent logs, and electronic timestamps.
*   **Action:** Directly contact site coordinators to upload or verify the specific version number for the 62 "unknown" subjects.
**Rationale:** Rule 9 forbids assuming scope (all affected or none affected) when records are incomplete. We must establish the factual universe of exposure before reporting final counts.

### 9. The Known Nerve-Weakness Event
**Directive:** The site investigator managing this specific subject must be instructed to disclose the omission error to that subject immediately. Explain that while the event resolved, the lack of prior risk disclosure was a study failure. Document this interaction separately from standard Adverse Event reporting.
**Rationale:** This event demonstrates the materiality of the omitted risk. Failing to inform this subject now constitutes ongoing harm regarding their autonomy and understanding of their medical history (Rule 1 & Rule 6).

### 10. Preservation, Privilege, and Proposed PDF Replacement
**Directive:** **ISSUE STOP-ORDER TO CHIEF SCIENTIFIC OFFICER.**
*   Prohibit the replacement of version 4.2 PDFs with version 4.3 in the database.
*   Instruct staff to preserve all current records (including v4.2) exactly as they are, including any document-conversion errors.
*   Legal analysis regarding this error may be privileged; however, Rule 10 clarifies that privilege does not excuse the duty of candor to oversight bodies or the requirement to preserve the audit trail. Overwriting files violates Rule 8 and creates legal liability for spoliation of evidence.
**Rationale:** Rule 8 requires preserving every consent version and signed form. Tampering with the file to "clean" it is a critical violation that will compound the regulatory breach.

### 11. Concrete Sequence: Next 72 Hours and 7 Days

*   **Wednesday (Day of Discovery, 10:00 a.m.)**
    *   Notify all Site Investigators: Stop all new enrollment and nonurgent interventions immediately.
    *   Instruct CSO: Do not alter database files. Preserve audit trail (Rule 8).
    *   Initiate version audit for the 62 "unknown" subjects via direct site contact (Rule 9).

*   **Wednesday (Day of Discovery, PM)**
    *   Prepare Emergency Ethics Board Submission packet (Defect description, Corrected Form v4.3).
    *   Draft initial notification letter to EB and Regulator (holding for final submission deadline but prepared now).
    *   Contact the specific subject with nerve weakness; arrange immediate disclosure meeting.

*   **Thursday (Day 2)**
    *   **Emergency Ethics Board Review.** Submit defect report and corrected consent form. Seek urgent approval for re-consent.
    *   Receive EB verbal or preliminary written approval.
    *   Sites begin re-consenting the 12 scheduled implant subjects using the newly approved form (Rule 5).

*   **Friday (Day 3)**
    *   Implantations proceed only for successfully re-consented subjects.
    *   Submit formal Ethics Board Report (if not already fully submitted Thursday) to meet the 5-business-day deadline buffer.

*   **Saturday – Monday**
    *   Continue version audit for remaining subjects.
    *   Initiate contact plan for subjects who completed interventions regarding new risk info (Rule 6).

*   **Tuesday (Day 5 - Business Day Deadline)**
    *   Finalize and formally transmit Ethics Board Report (Rule 4: Within 5 business days).

*   **Wednesday (Day 7 - Calendar Deadline)**
    *   File formal report with the Device Regulator (Rule 4: Within 7 calendar days). Include details of the omission, the AE involving the v4.2 subject, and corrective actions taken.

**Legal Warning:** Any deviation from this plan—specifically continuing implants without re-consent or altering digital records—will result in severe regulatory sanctions and potential liability for fraud or negligence. Proceed strictly according to Rules 1–10 of the Governing Law provided.